Adults with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event who received the oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor enlicitide ...

Per the 2018 American Heart Association/American College of Cardiology Multisociety Guideline for the Management of Blood Cholesterol (2018 AHA/ACC Guideline), [1] the cardiologist should discuss the ...

In patients with ASCVD who receive dialysis, statins decrease risk for MACE and all-cause mortality. Statins are associated with a decrease in all-cause mortality and major adverse cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Ten-year predicted ASCVD risk of 4% or more may serve as an adequate threshold for statin initiation based on ...

“Our analysis highlights the particular importance of adequate CVD prevention measures when considering treatment with tofacitinib for patients with RA and elevated CV risk, and particularly those ...

A once-a-day tablet called enlicitide is reshaping expectations for cholesterol care, cutting low density lipoprotein, or ...

The path to atherosclerotic cardiovascular disease (ASCVD) often starts in youth, as significantly abnormal lipid levels typically track into adulthood and lay the groundwork for clinical events in ...

Taking into account estimated 30-year risk of atherosclerotic cardiovascular disease (ASCVD) enables clinicians to identify which patients may benefit from starting primary-prevention strategies ...

HDL, the so-called good cholesterol, appears to influence treatment decisions around statin therapy, according to an analysis in JACC: Advances. Compared with people who have normal HDL-cholesterol ...

Among the effective options to reduce "bad" low-density lipoprotein (LDL) cholesterol levels, statins are the cornerstone of treatment. These drugs reduce the cholesterol your body makes and help ...